Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Targeting arginine methylation in colorectal cancer
EF 2022-23
Résumé
Colorectal cancer (CRC) is the second-leading cause of cancer mortality and the third-leading cancer diagnosis globally. In 2020, 935,000 deaths and over 1.9 million new diagnoses were estimated. While surgery and combination chemotherapy remain the first methods of treatment, in many cases, patients diagnosed with CRC often develop resistance to drug treatments, and their disease may return even after initial treatments were successful. Resistance to therapies as well as the return of CRC can be attributed to cancer stem cells (CSCs), a group of cancer cells which are not only unresponsive to standard treatments but survive treatment and cause cancer regrowth. Therefore, there is a need for new therapeutic avenues. Protein arginine methyltransferases (PRMTs) have been identified as promising therapeutic targets due to their abundance in cancer, as well as their association with cancer progression. PRMTs regulate splicing, the process by which a genetic message is formed. In cancer, splicing is hijacked, generating genetic messages promoting the survival of cancer cells. Cancer therapies often elicit a response resembling the one initiated when viruses infect cells that can subsequently lead to cell death and immune system activation. Modulating splicing produces a similar response and this type of antiviral response also enables the immune system to recognize and destroy cancer cells. By regulating PRMTs, we will alter splicing and harness the cellular antiviral immune response to eradicate CRC.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486479
Name
Cao Michelle A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting arginine methylation in colorectal cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiviral Immune Response; Arginine Methylation; Cancer Stem Cells; Colorectal Cancer; Gene Expression; Protein Arginine Methyltransferases; Splicing
Abstract
Colorectal cancer (CRC) is the second-leading cause of cancer mortality and the third-leading cancer diagnosis globally. In 2020, 935,000 deaths and over 1.9 million new diagnoses were estimated. While surgery and combination chemotherapy remain the first methods of treatment, in many cases, patients diagnosed with CRC often develop resistance to drug treatments, and their disease may return even after initial treatments were successful. Resistance to therapies as well as the return of CRC can be attributed to cancer stem cells (CSCs), a group of cancer cells which are not only unresponsive to standard treatments but survive treatment and cause cancer regrowth. Therefore, there is a need for new therapeutic avenues. Protein arginine methyltransferases (PRMTs) have been identified as promising therapeutic targets due to their abundance in cancer, as well as their association with cancer progression. PRMTs regulate splicing, the process by which a genetic message is formed. In cancer, splicing is hijacked, generating genetic messages promoting the survival of cancer cells. Cancer therapies often elicit a response resembling the one initiated when viruses infect cells that can subsequently lead to cell death and immune system activation. Modulating splicing produces a similar response and this type of antiviral response also enables the immune system to recognize and destroy cancer cells. By regulating PRMTs, we will alter splicing and harness the cellular antiviral immune response to eradicate CRC.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cao, Michelle A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~